A preliminary evaluation of dexamethasone palmitate emulsion: A novel intravitreal sustained delivery of corticosteroid for treatment of macular Edema

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 2, 2013, Pages 258-269

  Daull, Philippe ^a   Paterson, Christopher A ^b   Kuppermann, Baruch D ^c   Garrigue, Jean Sébastien ^a  

^a Novagali Pharma   (France)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; PALMITIC ACID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; BLOOD; BLOOD VESSEL PERMEABILITY; CAT; CHOROID; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ELECTRORETINOGRAPHY; EMULSION; FEMALE; HISTOPATHOLOGY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIMIT OF QUANTITATION; LOW DRUG DOSE; MALE; MINIPIG; NONHUMAN; OPHTHALMOSCOPY; RABBIT; RAT; RETINA; RETINA MACULA EDEMA; SINGLE DRUG DOSE; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TONOMETRY; VALIDATION STUDY;

ADRENAL CORTEX HORMONES; ANIMALS; CATS; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; EMULSIONS; FEMALE; MACULAR EDEMA; MALE; PALMITIC ACID; RABBITS; RANDOM ALLOCATION; RATS; RATS, INBRED BN; SWINE; SWINE, MINIATURE; TREATMENT OUTCOME; VITREOUS BODY;

EID: 84875032452     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0044     Document Type: Article

References (36)

1. CDC. National Diabetes Fact Sheet, 2011. http://www.cdc.gov/diabetes/ pubs/Factsheet11.htm
2. Gillies, M.C., Simpson, J.M., Billson, F.A., Luo, W., Penfold, P., Chua, W., Mitchell, P., Zhu, M., & Hunyor, A.B. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch. Ophthalmol. 122:336-340, 2004.
3. Sutter, F.K., Simpson, J.M., & Gillies, M.C. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebocontrolled clinical trial. Ophthalmology. 111:2044-2049, 2004.
4. Thompson, J.T. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am. J. Ophthalmol. 141:629-637, 2006.
5. Jaffe, G., Martin, D., Callanan, D., Pearson, P., Levy, B., and Comstock, T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophtalmologie. 113: 1020-1027, 2006.
6. Mavrikakis, E., & Lam, W.C. Current trends of intravitreal steroid use in retinal diseases. Can. J. Ophthalmol. 44:147-153, 2009.
7. Takehana, Y., Kurokawa, T., Kitamura, T., Tsukahara, Y., Akahane, S., Kitazawa, M., & Yoshimura, N. Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat. Invest. Ophthalmol. Vis Sci. 40:459-466, 1999.
8. Yanagi, Y., Tamaki, Y., Inoue, Y., Obata, R., Muranaka, K., and Homma, N. Subconjunctival doxifluridine administration suppresses rat choroidal neovascularization through activated thymidine phosphorylase. Invest. Ophthalmol. Vis. Sci. 44:751-754, 2003.
9. Kato, A., Kimura, H., Okabe, K., Okabe, J., Kunou, N., Nozaki, M., & Ogura, Y. Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide. Retina. 25:503-509, 2005.
10. Edelman, J.L., & Castro, M.R. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp. Eye Res. 71:523-533, 2000.
11. Edelman, J.L., Lutz, D., & Castro, M.R. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-Aqueous barrier breakdown. Exp. Eye Res. 80:249-258, 2005.
12. Baldwin, H.A., McDonald, T.O., & Beasley, C.H. Slit-lamp examination of experimental animal eyes. II. Grading scales and photographic evaluation of Induced pathological conditions. J. Soc. Cosmet. Chem. 24:181-195, 1973.
13. McDonald, T.O., & Shadduck, J.A. Eye irritation. In: Marzulli, F.N., & Maibach, H.I., eds. Advances in Modern Toxicology: Dermatoxicology and Pharmacology. Washington, DC: Hemisphere Publishing Corporation; pp. 139-191, 1977.
14. Bhattacherjee, P., Paterson, C.A., Spellman, J.M., Graff, G., and Yanni, J.M. Pharmacological validation of a feline model of steroid-induced ocular hypertension. Arch. Ophthalmol. 117:361-364, 1999.
15. Kuper, C.F., Harleman, J.H., Richter-Reichelm, H.B., and Vos, J.G. Histopathologic approaches to detect changes indicative of immunotoxicity. Toxicol. Pathol. 28:454-466, 2000.
16. Hubert, P., Nguyen-Huu, J.J., Boulanger, B., Chapuzet, E., Chiap, P., Cohen, N., Compagnon, P.A., Dewe, W., Feinberg, M., Lallier, M., Laurentie, M., Mercier, N., Muzard, G., Nivet, C., & Valat, L. Validation of quantitative analytical procedure, Harmonization of approaches. STP Pharma Pratiques. 13:101-138, 2003.
17. Cunningham, M.A., Edelman, J.L., & Kaushal, S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv. Ophthalmol. 53:139-149, 2008.
18. Boyer, D.S., Faber, D., Gupta, S., Patel, S.S., Tabandeh, H., Li, X.Y., Liu, C.C., Lou, J., & Whitcup, S.M. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 31:915-923, 2011.
19. Zucchiatti, I., Lattanzio, R., Querques, G., Querques, L., Del Turco, C., Cascavilla, M.L., & Bandello, F. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica. 228:117-122, 2012.
20. Kiernan, D.F., & Mieler, W.F. Intraocular corticosteroids for posterior segment disease: 2012 update. Expert Opin. Pharmacother. 13:1679-1694, 2012.
21. Stewart, M.W. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr. Diab. Rep. 12:364-375, 2012.
22. Herrero-Vanrell, R., Cardillo, J.A., & Kuppermann, B.D. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin. Ophthalmol. 5:139-146, 2011.
23. Lee, V.H., Iimoto, D.S., & Takemoto, K.A. Subcellular distribution of esterases in the bovine eye. Curr. Eye Res. 2:869-876, 1982.
24. Lee, V.H., Chang, S.C., Oshiro, C.M., & Smith, R.E. Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation. Curr. Eye Res. 4:1117-1125, 1985.
25. Stampfli, H.F., & Quon, C.Y. Polymorphic metabolism of flestolol and other ester containing compounds by a carboxylesterase in New Zealand white rabbit blood and cornea. Res. Commun. Mol. Pathol. Pharmacol. 88:87-97, 1995.
26. Kim, J.K., Yuan, H., Nie, J., Yang, Y.T., Leggas, M., Potter, P.M., Rinehart, J., Jay, M., & Lu, X. High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery. Small. 8:2895-2903, 2012.
27. Chang-Lin, J.E., Attar, M., Acheampong, A.A., Robinson, M.R., Whitcup, S.M., Kuppermann, B.D., & Welty, D. Pharmacokinetics and pharmacodynamics of a sustainedrelease dexamethasone intravitreal implant. Invest. Ophthalmol. Vis. Sci. 52:80-86, 2011.
28. Abraham, S.M., Lawrence, T., Kleiman, A., Warden, P., Medghalchi, M., Tuckermann, J., Saklatvala, J., & Clark, A.R. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 203:1883-1889, 2006.
29. Barnes, P.J. Corticosteroid effects on cell signalling. Eur. Respir. J. 27:413-426, 2006.
30. Chang-Lin, J.E., Burke, J.A., Peng, Q., Lin, T., Orilla, W.C., Ghosn, C.R., Zhang, K.M., Kuppermann, B.D., Robinson, M.R., Whitcup, S.M., & Welty, D.F. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 52:4605-4609, 2011.
31. Haller, J.A., Kuppermann, B.D., Blumenkranz, M.S., Williams, G.A., Weinberg, D.V., Chou, C., & Whitcup, S.M. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch. Ophthalmol. 128:289-296, 2010.
32. Pearson, P.A., Comstock, T.L., Ip, M., Callanan, D., Morse, L.S., Ashton, P., Levy, B., Mann, E.S., & Eliott, D. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 118:1580-1587, 2011.
33. Kuppermann, B.D., Blumenkranz, M.S., Haller, J.A., Williams, G.A., Weinberg, D.V., Chou, C., & Whitcup, S.M. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. 125:309-317, 2007.
34. Zhang, X., Krishnamoorthy, R.R., Prasanna, G., Narayan, S., Clark, A., & Yorio, T. Dexamethasone regulates endothelin-1 and endothelin receptors in human nonpigmented ciliary epithelial (HNPE) cells. Exp. Eye Res. 76: 261-272, 2003.
35. Clark, A.F., Lane, D., Wilson, K., Miggans, S.T., and McCartney, M.D. Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol. Invest. Ophthalmol. Vis. Sci. 37:805-813, 1996.
36. Petersen, A., Carlsson, T., Karlsson, J.O., Jonhede, S., and Zetterberg, M. Effects of dexamethasone on human lens epithelial cells in culture. Mol. Vis. 14:1344-1352, 2008.